✦ LIBER ✦

Chemotherapy with a weekly administration of docetaxel for metastatic Hormone Refractory Prostate Cancer (HRPC). Evaluation of tolerance, Quality of Life (QOL), and clinical benefit

✍ Scribed by Gwenaelle Gravis; Frank Bladou; Naji Salem; Geneviève Macquar; Gérard Serment; Jacques Camerlo; Dominique Maranin; Patrice Viens

Book ID: 118643995
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 182 KB
Volume: 1
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(02)80617-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly administration of docetaxel for s

Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma : Evaluation of clinical benefit, quality of life, and tolerance

✍ Gwenaelle Gravis; Franck Bladou; Naji Salem; Geneviève Macquart-Moulin; Gérard S 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND The current Phase II study investigated the clinical benefit, impact on quality of life (QOL), and tolerability of weekly docetaxel in symptomatic patients with metastatic hormone‐refractory prostate carcinoma (HRPC). ## METHODS Patients received weekly docetaxel 35 mg/

Early results of a multicenter phase 2 s

Early results of a multicenter phase 2 study: Weekly docetaxel and intermittent estramustin as combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC)

✍ U. Steiner; K. Miller; S. Machtens; B. Backhaus; M. Siegsmund 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Quality of life as a potential predictor

Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer

✍ Patrick W. Sullivan; Joel B. Nelson; Parvez M. Mulani; Darryl Sleep 📂 Article 📅 2006 🏛 Springer Netherlands 🌐 English ⚖ 183 KB